Azathioprine Dosing by Weight
Start azathioprine at 1 mg/kg/day in adults and 2.0-2.5 mg/kg/day in children, with the dose gradually increased to 2 mg/kg/day in adults as tolerated during maintenance therapy. 1
Adult Dosing
The most recent 2025 British Society of Gastroenterology guidelines provide clear weight-based dosing recommendations for azathioprine in autoimmune hepatitis, which serve as the standard approach across indications 1:
- Initial dose: 1 mg/kg/day (moderate evidence, weak recommendation)
- Maintenance dose: Can be gradually increased from 1 to 2 mg/kg/day as steroid doses are reduced, with appropriate blood count monitoring 1
The 2025 EASL guidelines for autoimmune hepatitis similarly recommend starting at 50 mg/day and gradually increasing to 1-2 mg/kg/day 2. The 2025 AGA Crohn's disease guidelines specify 2-2.5 mg/kg/day for azathioprine when used as monotherapy in patients with normal drug metabolism 3.
Context-Specific Dosing in Adults
For renal transplantation, the FDA label indicates higher initial dosing: 3-5 mg/kg daily beginning at transplant, with reduction to maintenance levels of 1-3 mg/kg/day 4.
For rheumatoid arthritis, start at approximately 1.0 mg/kg (50-100 mg) given once daily or twice daily. The dose may be increased by 0.5 mg/kg increments at 4-week intervals after 6-8 weeks if needed, up to a maximum of 2.5 mg/kg/day 4.
Pediatric Dosing
Children require higher weight-based doses than adults: 2.0-2.5 mg/kg/day 1. This higher dosing requirement in children is supported by research showing that early-onset IBD patients (age <6 years) required median doses of 2.7 mg/kg/day compared to 2.0 mg/kg/day in older children, likely due to elevated thiopurine methyltransferase (TPMT) activity 5.
The 2014 ECCO/ESPGHAN pediatric Crohn's disease guidelines note that higher azathioprine doses of 2.5 mg/kg/day were more effective than lower doses of 1.0 or 2.0 mg/kg/day in adults, and that doses up to 3 mg/kg/day have been used in pediatric IBD, though with a 30% discontinuation rate 6.
Critical Dosing Modifications
TPMT and NUDT15 Deficiency
Before starting azathioprine, measure TPMT enzyme activity to exclude homozygous deficiency (strong recommendation) 1:
- Homozygous TPMT or NUDT15 deficiency: Consider alternative therapies due to severe toxicity risk. If azathioprine must be used, substantial dose reduction is required 1, 4
- Heterozygous TPMT or NUDT15 deficiency: Dosage reduction is recommended, though the 2025 BSG guidelines note insufficient evidence for routine reduction of the initial dose in heterozygous TPMT deficiency 1. The FDA label recommends dose reduction for heterozygous deficiency 4
- Patients heterozygous for both TPMT and NUDT15: Require more substantial dosage reductions 4
Low Body Weight Considerations
Recent 2026 research identified body weight <47.35 kg as a significant risk factor for serious azathioprine-related adverse events (OR 2.82,95% CI 1.55-5.15) in Japanese patients with rheumatic diseases 7. This suggests particular caution and potentially lower initial dosing in patients with very low body weight, though specific dose adjustments are not established in guidelines.
Renal Dysfunction
Patients with renal dysfunction, especially oliguric patients with tubular necrosis post-transplant, may have delayed clearance and require lower doses 4. The FDA label recommends dose reduction in renal impairment, though specific adjustments are not provided.
Dose Escalation Strategy
The 2025 BSG guidelines recommend a response-guided approach 1:
- Start azathioprine at 1 mg/kg/day (can delay introduction by 2 weeks after starting steroids, though no benefit to delaying beyond this) 1
- As prednisolone is tapered over 1-3 months to 5-10 mg/day, gradually increase azathioprine from 1 to 2 mg/kg/day
- Monitor blood counts appropriately throughout dose escalation
Common Pitfalls
- Underdosing in children: Failing to use the higher 2.0-2.5 mg/kg/day doses needed in pediatric patients leads to suboptimal response
- Premature dose escalation: Azathioprine takes up to 8 weeks to reach steady-state metabolite levels 1, so dose adjustments should not be made too quickly
- Ignoring TPMT testing: Not checking TPMT before initiation misses the 0.3% of patients with homozygous deficiency at very high risk of severe myelosuppression 1
- Weight-based dosing in very obese patients: For patients ≥40 kg, consider using adult maximum doses rather than continuing weight-based escalation to avoid excessive dosing 8
Monitoring Requirements
Routine monitoring of complete blood counts and liver function tests is mandatory when using azathioprine 3. Azathioprine should be promptly reduced or stopped if significant bone marrow depression occurs, and stopped immediately for severe adverse events like pancreatitis 1.